Biosimilars have never been assured market success. The first oncology and oncology support therapies that were approved as biosimilars gained fairly rapid adoption, however, despite price points that were not always deeply discounted relative to the reference product. With the publication of Samsung Bioepis’ latest Biosimilar Market Report, covering data through the first quarter of … Continue reading Which Biosimilar Brands Are Struggling to Survive?